Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis

• Hoofdauteurs: Mikhail M. Kostik (Auteur), Eugenia A. Isupova (Auteur), Konstantin Belozerov (Auteur), Tatyana S. Likhacheva (Auteur), Evgeny N. Suspitsin (Auteur), Rinat Raupov (Auteur), Vera V. Masalova (Auteur), Irina A. Chikova (Auteur), Margarita F. Dubko (Auteur), Olga V. Kalashnikova (Auteur), Vyacheslav G. Chasnyk (Auteur), Randy Q. Cron (Auteur)
• Formaat: Boek
• Gepubliceerd in: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

ObjectiveMacrophage activation syndrome (MAS) is a life-threatening, potentially fatal condition associated with systemic juvenile idiopathic arthritis (sJIA). Interleukin-1 (IL-1) is a key cytokine in the pathogenesis of sJIA MAS. Many cases of MAS are medically refractory to traditional doses of b...